VistaGen Therapeutics, Inc. (Vistagen), fomerly Excaliber Enterprises, Ltd., is a biotechnology company. The Company's integrated stem cell biology platform, Human Clinical Trials in a Test Tube, is designed to provide an early indication, or prediction, of the cardiac toxicity of drug candidates before they are ever tested in humans. The Company's products include CardioSafe 3D, LiverSafe 3D and AV-101. CardioSafe 3D is a three-dimensional biological assay (screening) system that uses human heart cells to screen for cardiac toxicity. On May 11, 2011, Vistagen Therapeutics, Inc., a California corporation, merged with Excaliber Merger Subsidiary, Inc., which is a subsidiary of the Company. Cato Holding Company acquired its Vistagen shares and warrants in a number of transactions between August 30, 2001 and May 10, 2011.
|Headquarters||Suite #8, 384 Oyster Point Blvd|
SOUTH SAN FRANCISCO, CA, United States 94080
|President, Chief Scientific Officer, Director||H. Ralph Snodgrass|
|Chief Executive Officer, Director||Shawn Singh|
|Chief Financial Officer||Jerrold Dotson|
|Vice President - Corporate Development, Secretary||A. Franklin Rice|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||20.1M||Book Value||$-0.34|
|VistaGen Therapeutics Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.